• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Lynn Yoffee

Lynn Yoffee

lynn.yoffee@clarivate.com
Articles

ARTICLES

Queue Up! Early Stage VC Funding in China Has Legs

Nov. 14, 2013
By Lynn Yoffee
BEIJING – You’re not in the circle if you’re not talking China. That’s one Chinese venture capitalist’s take on things. His colleagues were optimistic and confident, too, as they described the biopharmaceutical investment landscape in a panel focused on early stage VC funding at BIO’s Convention here Wednesday.
Read More

Opportunity Abounds, but China’s Sector Struggles to Mature

Nov. 12, 2013
By Lynn Yoffee

BEIJING – In the shadow of the Third Plenum – a gathering this week of China’s ruling Communist Party members who likely will deliver major government reforms – and the day after what’s billed as the world’s biggest e-commerce shopping spree known as Singles Day (during which Chinese consumers spent an estimated $5 billion), biopharmaceutical executives gathered at BIO’s Convention in China to sort through the challenges of this flummoxed industry.


Read More

An Asia Strategy is Not Optional

Oct. 30, 2013
By Lynn Yoffee
"If you plan to be around five or 10 years from now, you have to have a Chinese strategy." That poignant comment in a BioWorld Today article came from Joshua Boger in 2011. The founder and former CEO of Vertex Pharmaceuticals Inc., and now executive chairman of Alkeus Pharmaceuticals Inc., had just returned from China where Shanghai Syntheall Pharmaceuticals Co. Ltd., a manufacturing subsidiary of Wuxi Apptec Co. Ltd., is the manufacturing site for starting materials for Vertex's hepatitis C drug Incivek (telaprevir). A combined massive government investment, a growing appetite for capitalism, and a shift from pharmaceutical industry service...
Read More

Biotech’s White Knight (aka Serial Cheater) Gets Prison Time, Finally

May 3, 2013
By Lynn Yoffee
It’s been 16 years since I first reported in BioWorld Today that David Blech was charged with securities fraud. In April 1997, I reached him at his New York office a few days after his arraignment in a U.S. District Court. Though he wouldn’t comment on the case, he chided me repeatedly for using the word “arrested,” insisting that I tell our readers he “appeared voluntarily” for the arraignment, still worried about his reputation ‑ as if it wasn’t already rubbish. Frankly, I’m satisfied he’s going to serve time. Angry that our judicial system can’t penalize him with a longer...
Read More

Open Innovation: Is an Old Concept Ready for Prime Time?

April 23, 2013
By Lynn Yoffee
CHICAGO – Big pharmas and biotechs have been flirting with the concept of open innovation – collaborative sharing of data to speed up the drug development process – for years. In fact, it has been more hype than substance.
Read More

Biopeople to Meet at BIO2013: Inside the World of Biotech’s Luminaries, Titans and Brainiacs

April 19, 2013
By Lynn Yoffee
Partnering, networking and making new friends are all top-of-the-agenda for the biopharma industry’s largest U.S. gathering. As you’re preparing to join 16,500+ of your colleagues at the 2013 BIO International Convention in Chicago, we’d like to introduce you to a few standouts featured in the stories below. Also, come meet the BioWorld people, who are pretty interesting, too, at booth 1573. Plus, you can collect BioWorld’s giveaway, which is both practical and sentimental. For 15 years, Publisher Donald R. Johnston has masterminded the creation of our lids. It’s a hotly sought after gift, so come early before we run out....
Read More

S1 Biopharma Aims for Female Viagra for HSDD Sans Hormones

Feb. 4, 2013
By Lynn Yoffee
When Nick Sitchon set out to identify a first product for his start-up, S1 Biopharma Inc., the medical school dropout turned entrepreneur chatted with his mother and hit (potential) pay dirt with her very first idea: "Why not develop something for me and my low libido?"
Read More

Biosimilar Pioneers Play Their Strategy Cards Close to Vest

Jan. 10, 2013
By Lynn Yoffee
With an established reputation for its generic drugs, Mumbai, India-based Lupin Ltd. has expanded into biosimilars in its quest to become a global biopharma powerhouse. But like the foggy view from the 32nd-floor penthouse location of the Asia track at the J.P. Morgan Healthcare Conference Wednesday morning, the firm's chief financial officer provided limited insight into the company's biosimilars strategy despite audience questions.
Read More

FDA Offers Orexigen Express Route to Contrave Resubmission

Jan. 9, 2013
By Lynn Yoffee
If just 6 percent of diabetes patients who are obese take Orexigen Therapeutics Inc.'s Contrave (naltrexone SR/bupropion SR), the company will reach $1 billion in sales in short order – assuming the FDA grants approval. Given the agency's action this week, company execs have reason to feel confident.
Read More

Biopharma's Next Act: Think Global, Go Virtual, Partner More

June 21, 2012
By Lynn Yoffee
BOSTON – "Chris Viehbacher, tear down this wall!" That was the Reagan-like plea from a venture capitalist to Sanofi SA's CEO in a keynote panel at BIO 2012, which featured industry heavyweights who predicted what will happen in the next decade for the biopharma sector and provided solutions for what's needed to keep the drug development engine fueled.
Read More
View All Articles by Lynn Yoffee

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 30, 2025.
  • 3d rendering of bispecific antibodies

    Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

    BioWorld
    Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 27, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe